Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | GPR6 | P46095 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | ALPL | P05186 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | PIK3C3 | Q8NEB9 | 3/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29836179 | 0.61 | SMN1; SMN2 (0.48) | GSK3BP2RX7MAOBRIPK1 | |
| SCHEMBL3967997 | 0.61 | SMN1; SMN2 (0.48) | GSK3BP2RX7MAOBRIPK1 | |
| SCHEMBL20609634 | 0.59 | MAOB (0.49) | GSK3BMAOBRIPK1HTT | |
| SCHEMBL10585341 | 0.58 | DPP4 (0.46) | GSK3BMAOB | |
| SCHEMBL6327566 | 0.58 | DPP4 (0.46) | GSK3BMAOB | |
| SCHEMBL1613106 | 0.58 | DPP4 (0.46) | GSK3BMAOB | |
| SCHEMBL4251045 | 0.58 | L3MBTL1 (0.53) | GSK3BALPLL3MBTL1HTT | |
| SCHEMBL1699443 | 0.58 | MAOB (0.51) | P2RX7MAOBRIPK1 | |
| SCHEMBL15735500 | 0.58 | IDO1 (0.46) | GSK3BP2RX7MAOBRIPK1 | |
| SCHEMBL27959396 | 0.58 | IDO1 (0.46) | GSK3BP2RX7MAOBRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221154-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | PFIZER INC | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221154-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | TYMP, IMPDH1, POLB | GSK3B 238/4885P2RX7 4306/4885MAOB 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.